Zahiu Teodora, Mihu Carmen Mihaela, Bosca Bianca A, Mărginean Mariana, Mocan Lavinia Patricia, Ștefan Roxana-Adelina, Suflețel Rada Teodora, Mihu Carina, Melincovici Carmen Stanca
Radiology and Imaging Department, County Emergency Hospital, 400006 Cluj-Napoca, Romania.
Department of Morpho-Functional Sciences, Discipline of Histology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Diagnostics (Basel). 2025 May 24;15(11):1323. doi: 10.3390/diagnostics15111323.
Pleural mesothelioma (PM) is a rare disease, which is going to be a global medical concern in the 21st century, because of its aggressiveness, late diagnosis, and insufficient therapies. This review seeks to enhance the comprehension of medical professionals regarding the risk factors and environmental influences that contribute to the development of the disease, as well as its underlying mechanisms. In addition, we aim to provide a schematic yet thorough overview of diagnostic techniques in PM, emphasizing the significance of the immunohistochemical markers BAP1 and MTAP, with the latter serving as an almost ideal surrogate for the gold-standard diagnostic approach, FISH p16/CDKN2A deletion. The scientific world is grappling with BAP1, MTAP, and the tumour inflammatory microenvironment, because they are the key for personalized treatments and palliative care in this disease. Considering that the survival rate for patients with PM seldom surpasses five years, every moment is significant. Therefore, our article also highlights recent advancements in clinical assessments related to prognostic scoring and treatment options. PM is a complex disease, with gradual progression over decades, which requires further investigation covering the prevention, mutations, diagnosis and treatment.
胸膜间皮瘤(PM)是一种罕见疾病,鉴于其侵袭性、诊断延迟和治疗手段不足,它将成为21世纪全球医学关注的问题。本综述旨在增进医学专业人员对导致该疾病发生的风险因素和环境影响及其潜在机制的理解。此外,我们旨在对PM的诊断技术提供一个简要而全面的概述,强调免疫组化标志物BAP1和MTAP的重要性,其中后者几乎可作为金标准诊断方法——FISH检测p16/CDKN2A缺失的理想替代方法。科学界正在努力研究BAP1、MTAP和肿瘤炎性微环境,因为它们是该疾病个性化治疗和姑息治疗的关键。鉴于PM患者的生存率很少超过五年,每一刻都至关重要。因此,我们的文章还重点介绍了与预后评分和治疗选择相关的临床评估的最新进展。PM是一种复杂疾病,病程长达数十年且呈渐进性发展,需要在预防、突变、诊断和治疗等方面开展进一步研究。
Diagnostics (Basel). 2025-5-24
Int J Mol Sci. 2023-8-3
Am Soc Clin Oncol Educ Book. 2023-5
Medicine (Baltimore). 2022-12-30
Oncol Nurs Forum. 2022-10-20